welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.
The ideal treatment for thyroid eye disease would decrease inflammation, reduce proptosis and double vision, improve quality of life, have minimal adverse effects and minimize the need for surgical treatment, Raymond S. Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, said in a presentation on the topic at Hawaiian Eye 2020.
Additionally, this treatment would target the long-term manifestations of the disease rather than the short-term manifestations that are primarily targeted with steroids and other second line agents, he said.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
Graves’ Eye Disease FAQWhat is the Thyroid Gland? The thyroid ...
Beyond the Orbit: TED Damage Is Also PsychosocialThyroid eye disease can have a significa...
New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durabil...Horizon Therapeutics plc announced posit...
Warning Signs of Graves’ Disease and Thyroid Eye Diseasehttps://mms.businesswire.com/media/20190...
Relation between Therapy Options for Graves’ Disease and the Course of Graves’ Ophthalmopathy: A Systema...Background: The relation between therap...
A New Era in the Treatment of Thyroid Eye DiseasePurpose: Improved understanding of thyr...
Graves’ Eye DiseaseWhat is the Thyroid Gland? The thyroid ...